Io­n­is earns $40M on Spin­raza ad­vance; Five Prime ax­es In­hi­brx deal

⇨ Io­n­is is pick­ing up an­oth­er big check from Bio­gen re­lat­ed to the roll­out of Spin­raza. The biotech $IONS gar­nered $40 mil­lion on ap­proval of the price in Japan, bring­ing its to­tal take to $435 mil­lion.

⇨ Five Prime Ther­a­peu­tics is punt­ing its $452 mil­lion re­search pact — which came with a $10 mil­lion up­front — with In­hi­brx. The biotech axed the deal two days ago, ac­cord­ing to an SEC fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.